Clostridium difficile infection (CDI) affects a broad population and has become so widespread the Centers for Disease Control and Prevention rated C. difficile as an urgent threat in 2013.
recurrent disease in humans. [13] [14] [15] Identifying specific bacterial species most important for CDI prevention and treatment is essential with the ultimate therapeutic goal being targeted replacement of deficiencies.
Chang et al. characterized and compared the community structure of the human fecal microbiome in three control subjects without CDI, four who had an initial episode and three who had recurrent disease. Those with CDI were exposed to a variety of antimicrobials before inclusion in the study as risk factors for their disease. 16 Standard characterization of the microbiome was performed by using 16S rRNA-encoding gene sequence analysis to characterize the relative abundance of various phyla and the ecological diversity (e.g., Shannon Index). This study showed that patients with recurrent CDI have less diverse bacterial colonization with a deficiency of bacteroidetes and firmicutes. 16 A recent group of studies published as a single manuscript used a murine model of CDI combined with a human cohort to clarify microbiome changes with various antimicrobial's, correlate those changes with varying susceptibility to CDI, identify which species are most important for colonization resistance and understand the mechanism of their resistance. 17 To measure the susceptibility to CDI resulting from various antimicrobials, mice were initially exposed to the antibiotic, then infected with a standard amount of CDI, and finally had resistance measured by selectively culturing the stool and enumerating the volume of colony forming units at various time points; clindamycin caused long-lasting susceptibility to infection, ampicillin transient susceptibility and enrofloxacin no change with each respective antibiotic having distinct effects on the microbiome. 17 Specific features of the microbiome preserve colonization resistance as recovery only occurred when common bacterial diversity, measured using similar techniques to Chang et al., was seen among all groups and neither low personal microbiome diversity nor early antimicrobial exposure affected susceptibility. 17 Using the 16S rRNA sequence analysis, individual bacterial species abundance was estimated and resistance to CDI correlated with 11 specific species; the strongest association was with Clostridium scindens. This finding was corroborated in a human cohort. 17 To test whether the species identified are significant contributors to colonization resistance in the murine model, two therapies were given before antimicrobials inducing CDI: one included C. scidens alone and the second C. scidens and three abundant species in the human-and murine-resistance models. Both treatments lessened mortality and severity of disease compared with controls with the abundance of C. scidens correlating directly with resistance to infection. 17 Knowing that C. scidens has a unique intestinal function synthesizing secondary bile acids and that polymerase chain reaction measurement of the bile acid inducible operon gene (bai, a secondary bile acid biosynthesis gene) correlates with resistance to CDI, the study then showed that mice receiving prophylaxis with four species had the greatest resistance with the highest presence of bai. These mice had restored abundance of previously depleted secondary bile acids (e.g., deoxycholate and lithocholate). Of those four species restored, only the C. scidens is able to produce secondary bile acids suggesting additional mechanisms from other species might enhance colonization resistance but that secondary bile acids inhibit CDI in a dosedependent fashion.
This murine study shows bacteria such as C. scidens playing an integral role in colonization resistance and hypothesizes that its unique ability to convert secondary bile salts might be a mechanism of disease moderation or prevention. As the CDI epidemic worsens, a better understanding of the disease process, ways to target therapy and which bacterial species and their byproducts play roles in disease prevention and moderation will be critical for further development of therapy. Basic science studies such as those outlined in this manuscript will continue to be essential in the area of CDI. 
